Michael Chorny Laboratory

Led by Michael Chorny, PhD, researchers in the Chorny Laboratory are focused on developing tumor-targeted, nanoparticle-based cancer drugs to treat children with neuroblastoma and other pediatric malignancies. Using ultra small-sized (<100nm) biodegradable particles containing an experimental cancer drug, researchers in the Chorny Laboratory were able to reduce the tumor burden (with no systemic toxicity) in mouse models of neuroblastoma.

Different families of potent anticancer agents, including camptothecins, biodegradable derivative of staurosporine and others, are currently being evaluated in the nanocarrier delivery system as potential new treatments for high-risk neuroblastomas.

Future studies in the Chorny Laboratory will continue to focus on refinement of nanoparticle delivery systems that can be used to deliver anti-cancer drugs to treat neuroblastomas and other pediatric solid tumors in a more targeted and less toxic manner than existing treatment options.